Phathom Pharmaceuticals will host a webcast on October 29, 2026, to discuss Q3 2026 financial results and business updates.
Quiver AI Summary
Phathom Pharmaceuticals, Inc. announced it will host a live webcast on October 29, 2026, at 8:00 am EDT to discuss its third quarter 2026 financial results and provide a business update. The webcast will be accessible on the company's website, and a recording will be available for 90 days afterwards. Phathom is focused on developing and commercializing treatments for gastrointestinal diseases, notably marketing vonoprazan in the U.S. under the brand name VOQUEZNA® for various gastrointestinal conditions. Additional information is available on their website and social media platforms.
Potential Positives
- Phathom Pharmaceuticals is scheduled to report its third quarter 2026 financial results, which may provide transparency and insights into the company's financial health and performance.
- The company has in-licensed exclusive rights to vonoprazan, a novel treatment, highlighting its focus on developing innovative solutions for gastrointestinal diseases.
- Phathom actively markets vonoprazan in the United States under the VOQUEZNA brand, addressing significant medical needs associated with GERD and H. pylori infections.
Potential Negatives
- The press release lacks detailed financial projections or specific updates on the company's performance, which may lead to investor uncertainty.
- There is no mention of addressing any challenges or setbacks faced in the previous quarter, potentially indicating an underlying issue that has not been communicated.
- Hosting a live webcast implies that the company may have significant news to share; however, it could also indicate that there have been issues that require immediate transparency and communication with stakeholders.
FAQ
When will Phathom Pharmaceuticals announce its Q3 2026 financial results?
Phathom Pharmaceuticals will announce its Q3 2026 financial results on October 29, 2026, at 8:00 am EDT.
Where can I access the webcast for Phathom's financial results?
The webcast can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.
What product does Phathom Pharmaceuticals market in the U.S.?
Phathom Pharmaceuticals markets vonoprazan as VOQUEZNA® tablets and VOQUEZNA® TRIPLE PAK® for gastric-related conditions.
How long will the webcast recording be available?
The recording of the webcast will be available for 90 days following the conclusion of the call.
What diseases are Phathom Pharmaceuticals focused on treating?
Phathom Pharmaceuticals is focused on developing novel treatments for gastrointestinal diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHAT Revenue
$PHAT had revenues of $74.3M in Q2 2026. This is an increase of 88.02% from the same period in the prior year.
You can track PHAT financials on Quiver Quantitative's PHAT stock page.
You can access data on PHAT stock through the Quiver Quantitative API.
$PHAT Hedge Fund Activity
We have seen 78 institutional investors add shares of $PHAT stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP added 1,635,185 shares (+125.1%) to their portfolio in Q3 2026, for an estimated $11,936,850
- GOLDMAN SACHS GROUP INC added 1,151,836 shares (+183.9%) to their portfolio in Q2 2026, for an estimated $12,497,420
- POINT72 ASSET MANAGEMENT, L.P. added 1,022,193 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,090,794
- FRANKLIN RESOURCES INC added 976,324 shares (+98.2%) to their portfolio in Q2 2026, for an estimated $10,593,115
- GW&K INVESTMENT MANAGEMENT, LLC added 745,729 shares (+52.5%) to their portfolio in Q2 2026, for an estimated $8,091,159
- HSBC HOLDINGS PLC added 709,695 shares (+inf%) to their portfolio in Q2 2026, for an estimated $7,700,190
- MILLENNIUM MANAGEMENT LLC removed 647,075 shares (-16.1%) from their portfolio in Q2 2026, for an estimated $7,020,763
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
FLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 29, 2026, to report its third quarter 2026 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations . A recording will be available for 90 days following the conclusion of the call.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA
®
(vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA
®
TRIPLE PAK
®
(vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA
®
DUAL PAK
®
(vonoprazan tablets, amoxicillin capsules) for the treatment of
H. pylori
infection in adults. For more information about Phathom, visit the company’s website at
www.phathompharma.com
and follow on
LinkedIn
and
X
.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
[email protected]
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
[email protected]
© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
